Illumina to cut $100M in fiscal 2025 costs

Illumina to Cut $100 Million in Costs, Lowers Guidance Because of China Sales Ban
Diagnostic Kit Maker Illumina To Cut $100 Million In Costs, Lowers 2025 Profit Outlook Amid China Trade Restrictions
 · 10hFierce Biotech
Illumina aims to cut $100M in costs following China import ban
Illumina price target lowered to $115 from $135 at Canaccord
Canaccord lowered the firm’s price target on Illumina (ILMN) to $115 from $135 and keeps a Hold rating on the shares. The firm’s target
China Targets San Diego Biotech Firm in Broadening Blacklist
In a sign it is willing to go further in responding to President Trump’s tariffs, Beijing blocked more American companies from importing goods into China.
What's Left of Illumina's China Business After Tariff Retaliation: Heard on the Street
Illumina shareholders received a warning shot. In response to President Trump’s initial tariff measures, the Chinese government added the maker of gene-sequencing equipment to its list of “unreliable entities.
Illumina addresses recent developments in China
Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today responded to the March 4, 2025 notice from the China Ministry of Commerce ("MOFCOM") that Illumina is not permitted to export sequencing instruments into China.